Premium Nahrungsergänzungsmittel | artgerecht

PINP – Bone Formation Marker Explained

PINP (Procollagen Type I N-terminal Propeptide) is a blood marker for bone formation. It is used in the diagnosis and monitoring of osteoporosis and other bone diseases.

Regular tips about health Regular tips about health

Things worth knowing about "PINP"

PINP (Procollagen Type I N-terminal Propeptide) is a blood marker for bone formation. It is used in the diagnosis and monitoring of osteoporosis and other bone diseases.

What is PINP?

PINP stands for Procollagen Type I N-terminal Propeptide. It is a protein fragment released during the synthesis of type I collagen, the primary structural protein of bone. PINP is widely recognized as one of the most reliable laboratory markers for bone formation and is recommended by leading international organizations for use in the diagnosis and therapeutic monitoring of bone diseases.

How is PINP Produced?

Type I collagen is produced by specialized bone-building cells called osteoblasts. The process begins with the synthesis of a precursor molecule called procollagen. As procollagen is processed into mature collagen fibers, the N-terminal propeptide (PINP) is cleaved off and released into the bloodstream. The level of PINP in the blood therefore directly reflects osteoblast activity and the rate at which new bone is being formed.

Clinical Significance and Applications

Osteoporosis

PINP is a well-established bone turnover marker (BTM) and is recommended by the IOF (International Osteoporosis Foundation) and the IFCC (International Federation of Clinical Chemistry) as the reference marker for bone formation. Its clinical uses include:

Early assessment of fracture risk
Monitoring the response to osteoporosis therapy (e.g., bisphosphonates, denosumab, or teriparatide)
Evaluating treatment efficacy as early as 3–6 months after initiation

Other Indications

Beyond osteoporosis, PINP is also measured in the following conditions:

Paget's disease of bone: characterized by elevated bone remodeling rates
Bone metastases: in cancers such as prostate or breast cancer, for disease monitoring
Primary hyperparathyroidism: overactivity of the parathyroid glands affecting bone metabolism
Renal osteodystrophy: bone changes associated with chronic kidney disease
Growth assessment in children and adolescents: PINP levels are physiologically elevated during growth phases

How is PINP Measured?

PINP is measured from a simple blood sample (serum or plasma) using immunological assays such as ELISA or electrochemiluminescence immunoassay. Two main forms are distinguished:

Intact PINP: measures the complete trimeric propeptide; considered more specific and less affected by impaired kidney function
Total PINP: also captures monomeric fragments; commonly used in routine laboratory testing

For optimal comparability in follow-up measurements, the same assay method should be used consistently. Blood samples should ideally be taken in the morning under fasting conditions, as PINP levels show some diurnal variation.

Reference Values

Reference ranges may vary depending on the laboratory and assay method used. General reference values for adults using intact PINP assays are:

Premenopausal women: approx. 20–76 μg/l
Postmenopausal women: approx. 16–96 μg/l
Men: approx. 22–87 μg/l

Elevated values indicate increased bone formation, which may be physiological (e.g., in growing children or after fractures) or pathological (e.g., in Paget's disease or bone metastases). Low values may indicate reduced osteoblast activity and an increased risk of fractures.

PINP in Osteoporosis Treatment Monitoring

One of the most important applications of PINP is monitoring ongoing osteoporosis therapy. Under bone-building treatment with teriparatide (a synthetic parathyroid hormone analogue), PINP levels typically rise substantially, confirming the anabolic effect on bone. Conversely, under bone-resorption-inhibiting therapies such as bisphosphonates or denosumab, PINP levels decrease significantly, reflecting reduced bone turnover. A lack of decline may suggest poor treatment adherence or insufficient therapeutic response.

References

Vasikaran S. et al. - Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporosis International, 2011; 22(2):391–420.
Kanis J.A. et al. - European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International, 2019; 30(1):3–44.
World Health Organization (WHO) - Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843, Geneva, 1994.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.